Emerging drugs for the treatment of alopecia areata / Hassiel Aurelio Ramírez-Marín, Antonella Tosti
ABSTRACT Introduction Alopecia Areata (AA) is the second most common non-scarring hair loss disorder, with a prevalence of 1 in 1000 and a lifetime incidence of 2% worldwide. Data from a recent American study shows that from 68,121 patients with the diagnosis of AA, 37,995 (55.8%) were prescribed treatment for AA within a year of diagnosis, however there are still no therapies able to induce permanent remission, or treatments that guarantee hair regrowth/remissions in 100% of cases, especially in longstanding/severe AA. Recently, oral baricitinib has been approved for AA, being the first drug approved for this specific indication. Areas covered The current review will provide a summary of current pharmacological approaches and novel therapeutics in development. Expert opinion New and very effective drugs have become available for the treatment of severe AA, and many others are expected soon. However, even new, effective treatments are not effective in all patients and recurrence rates after treatment interruption are high. AA is a systemic disease with important impact on quality of life and should not be considered just as an aesthetic problem. Treatment of the disease should take in account and possibly also address treatment of comorbidities.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
|---|---|
| Enthalten in: |
Expert opinion on emerging drugs - 27(2022), 4, Seite 379-387 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ramírez-Marín, Hassiel Aurelio [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Themen: |
Alopecia |
|---|
| Umfang: |
1 Online-Ressource (9 p) |
|---|
| doi: |
10.1080/14728214.2022.2149735 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
KFL011130946 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL011130946 | ||
| 003 | DE-627 | ||
| 005 | 20230713210843.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230609s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/14728214.2022.2149735 |2 doi | |
| 035 | |a (DE-627)KFL011130946 | ||
| 035 | |a (KFL)prod_LgpH_10.1080/14728214.2022.2149735 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Ramírez-Marín, Hassiel Aurelio |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Emerging drugs for the treatment of alopecia areata |c Hassiel Aurelio Ramírez-Marín, Antonella Tosti |
| 264 | 1 | |c 2022 | |
| 300 | |a 1 Online-Ressource (9 p) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a ABSTRACT Introduction Alopecia Areata (AA) is the second most common non-scarring hair loss disorder, with a prevalence of 1 in 1000 and a lifetime incidence of 2% worldwide. Data from a recent American study shows that from 68,121 patients with the diagnosis of AA, 37,995 (55.8%) were prescribed treatment for AA within a year of diagnosis, however there are still no therapies able to induce permanent remission, or treatments that guarantee hair regrowth/remissions in 100% of cases, especially in longstanding/severe AA. Recently, oral baricitinib has been approved for AA, being the first drug approved for this specific indication. Areas covered The current review will provide a summary of current pharmacological approaches and novel therapeutics in development. Expert opinion New and very effective drugs have become available for the treatment of severe AA, and many others are expected soon. However, even new, effective treatments are not effective in all patients and recurrence rates after treatment interruption are high. AA is a systemic disease with important impact on quality of life and should not be considered just as an aesthetic problem. Treatment of the disease should take in account and possibly also address treatment of comorbidities | ||
| 653 | |a Alopecia treatment | ||
| 653 | |a alopecia areata | ||
| 653 | |a alopecia | ||
| 653 | |a JAK inhibitors | ||
| 653 | |a tofacitinib | ||
| 653 | |a baricitinib | ||
| 653 | |a ruxolitinib | ||
| 653 | |a ritlecitinib | ||
| 653 | |a jaktinib | ||
| 653 | |a upadacitinib | ||
| 653 | |a daxdilimab | ||
| 653 | |a rosnilimab | ||
| 653 | |a etrasimod | ||
| 653 | |a steroids | ||
| 653 | |a methotrexate | ||
| 653 | |a topical immunotherapy | ||
| 700 | 1 | |a Tosti, Antonella |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert opinion on emerging drugs |d Abingdon, Oxon : Routledge, Taylor & Francis, 2001 |g 27(2022), 4, Seite 379-387 |h Online-Ressource |w (DE-627)KFL000006033 |w (DE-600)2030079-7 |w (DE-576)302969306 |x 1744-7623 |7 nnns |
| 773 | 1 | 8 | |g volume:27 |g year:2022 |g number:4 |g pages:379-387 |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/tandf-ejournals-pharmazie/doi.org/10.1080/14728214.2022.2149735 |m X:KFL |x Resolving-System |y FID Access |z lizenzpflichtig |
| 912 | |a ZDB-1-TFE | ||
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 935 | |i IMPORT_0628_prod_LgpH_05 | ||
| 951 | |a AR | ||
| 952 | |d 27 |j 2022 |e 4 |h 379-387 | ||